A solitary fibrous tumor of the parotid gland: Case report

Introduction: Solitary fibrous tumor is a rare neoplasm that can affect any part of the body, also head and neck region. Etiology is unknown. The incidence is slightly higher in males, the age ranges from 11 to 79 years. Presentation of case: It's the first case in our country of left parotid solitary fibrous tumor, removed by partial parotidectomy with facial nerve preservation. Histology examination showed diffuse spindle-shaped cells proliferation, moderate polymorphism, low mitotic index (<4 mitoses per 10 HPF), partially bordered by fibrous capsule. Immunohistochemistry showed STAT6, CD34, CD99 positivity. Six-months follow-up didn't show sign of recurrence. Discussion: Solitary fibrous tumor is a mesenchymal spindle cell neoplasm with fibroblastic differentiation ubiquitous in soft tissues, that involved the head and neck region in 6 % of cases. Etiology is unknown. The possible pathogenesis is NAB2-STAT6 gene fusion. It's asymptomatic or symptoms are related to space-occupying mass. Diagnostic work up involves imaging, immunohistochemistry, histology. Radiographic finding may lead to incorrect assessment of the mass: the same imaging features are present in pleomorphic adenoma, the most frequent tumor of salivary glands. Conclusion: This case report aims to stress that, although rare, solitary fibrous tumor should be considered in differential diagnosis in case of indolent salivary gland mass, since it may require more invasive approach (e.g., total parotidectomy, adjuvant radiotherapy). It would like to highlight the role of multidisciplinary team to define the best therapy, tailored for the patient, as well as to give awareness to a rare but sometimes aggressive tumor

Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study

Elevation in liver transaminases is common in patients treated with the marine antitumor agent trabectedin. However, the impact of trabectedin-related transaminase elevations on treatment outcomes is unclear. This retrospective study investigated the correlation between liver tests abnormalities and treatment outcomes in patients with unresectable advanced or metastatic soft tissue sarcomas (STS) treated with trabectedin 1.5 mg/m2 once every 3 weeks at three reference centers in Italy. The effect of grade 3/4 elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) during the first two cycles and at any time during trabectedin treatment on progression-free survival (PFS) and overall survival (OS) were analyzed. Liver tests abnormalities during the first two cycles of chemotherapy or at any time during trabectedin treatment did not significantly affect PFS or OS. Nor were survival outcomes significantly different in the subgroups of patients with or without ALT/AST increases or with ALT/AST elevations ≥15 × the upper limit of normal (ULN) versus those with ALT/AST elevation <15 × ULN. Although liver tests abnormalities are common in patients treated with trabectedin, elevations in ALT and AST are usually transient, occur during the first two cycles of treatment, and do not appear to affect survival

Quasi-energy-independent solar neutrino transitions

Current solar, atmospheric, and reactor neutrino data still allow oscillation scenarios where the squared mass differences are all close to 10^-3 eV^2, rather than being hierarchically separated. For solar neutrinos, this situation (realized in the upper part of the so-called large-mixing angle solution) implies adiabatic transitions which depend weakly on the neutrino energy and on the matter density, as well as on the ``atmospheric'' squared mass difference. In such a regime of ``quasi-energy-independent'' (QEI) transitions, intermediate between the more familiar ``Mikheyev-Smirnov-Wolfenstein'' (MSW) and energy-independent (EI) regimes, we first perform analytical calculations of the solar nu_e survival probability at first order in the matter density, beyond the usual hierarchical approximations. We then provide accurate, generalized expressions for the solar neutrino mixing angles in matter, which reduce to those valid in the MSW, QEI and EI regimes in appropriate limits. Finally, a representative QEI scenario is discussed in some detail.Comment: Title changed; text and acronyms revised; results unchanged. To appear in PR

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis

We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line.All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 off or 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits.64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7-10.9) and 5 months (95% CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370).A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis

none14noWe retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 offor 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7-10.9) and 5 months (95% CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370). A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line.openVincenzi B.; Nannini M.; Fumagalli E.; Bronte G.; Frezza A.M.; De Lisi D.; Ceruso M.S.; Santini D.; Badalamenti G.; Pantaleo M.A.; Russo A.; Dei Tos A.P.; Casali P.; Tonini G.Vincenzi, B.; Nannini, M.; Fumagalli, E.; Bronte, G.; Frezza, A. M.; De Lisi, D.; Ceruso, M. S.; Santini, D.; Badalamenti, G.; Pantaleo, M. A.; Russo, A.; Dei Tos, A. P.; Casali, P.; Tonini, G

Analytical description of quasivacuum oscillations of solar neutrinos

We propose a simple prescription to calculate the solar neutrino survival probability P_{ee} in the quasivacuum oscillation (QVO) regime. Such prescription is obtained by matching perturbative and exact analytical results, which effectively take into account the density distribution in the Sun as provided by the standard solar model. The resulting analytical recipe for the calculation of P_{ee} is shown to reach its highest accuracy |\Delta P_{ee}| < 2.6 x 10^{-2} in the whole QVO range) when the familiar prescription of choosing the solar density scale parameter r_0 at the Mikheyev-Smirnov-Wolfenstein (MSW) resonance point is replaced by a new one, namely, when r_0 is chosen at the point of ``maximal violation of adiabaticity'' (MVA) along the neutrino trajectory in the Sun. The MVA prescription admits a smooth transition from the QVO regime to the MSW transition one. We discuss in detail the phase acquired by neutrinos in the Sun, and show that it might be of relevance for the studies of relatively short timescale variations of the fluxes of the solar \nu lines in the future real-time solar neutrino experiments. Finally, we elucidate the role of matter effects in the convective zone of the Sun.Comment: 25 pages (RevTeX) + 11 figures (postscript

Accelerator and Reactor Neutrino Oscillation Experiments in a Simple Three-Generation Framework

We present a new approach to the analysis of neutrino oscillation experiments, in the one mass-scale limit of the three-generation scheme. In this framework we reanalyze and recombine the most constraining accelerator and reactor data, in order to draw precise bounds in the new parameter space. We consider our graphical representations as particularly suited to show the interplay among the different oscillation channels. Within the same framework, the discovery potential of future short and long baseline experiments is also investigated, in the light of both the recent signal from the LSND experiment and the atmospheric neutrino anomaly.Comment: uuencoded compressed tar file. Figures (13) available by ftp to ftp://eku.sns.ias.edu/pub/lisi/ (192.16.204.30). Submitted to Physical Review

Supernova Neutrino-Nucleus Astrophysics

In this brief review we explore the role of neutrino-nucleus interactions in core-collapse supernovae and discuss open questions. In addition implications of neutrino mass and mixings in such environments are summarized.Comment: Revtex 4 figure

Solar neutrino oscillation parameters after first KamLAND results

We analyze the energy spectrum of reactor neutrino events recently observed in the Kamioka Liquid scintillator Anti-Neutrino Detector (KamLAND) and combine them with solar and terrestrial neutrino data, in the context of two- and three-family active neutrino oscillations. In the 2-neutrino case, we find that the solution to the solar neutrino problem at large mixing angle (LMA) is basically split into two sub-regions, that we denote as LMA-I and LMA-II. The LMA-I solution, characterized by lower values of the squared neutrino mass gap, is favored by the global data fit. This picture is not significantly modified in the 3-neutrino mixing case. A brief discussion is given about the discrimination of the LMA-I and LMA-II solutions with future KamLAND data. In both the 2- and 3-neutrino cases, we present a detailed analysis of the post-KamLAND bounds on the oscillation parameters.Comment: Revised version. Two figures adde

Global Analysis with SNO: Toward the Solution of the Solar Neutrino Problem

We perform a global analysis of the latest solar neutrino data including the SNO result on the CC-event rate. This result further favors the LMA solution of the solar neutrino problem. The best fit values of parameters we find are: \Delta m^2 = (4.8 - 5.0)10^{-5} eV^2, tan^2 \theta = 0.35 - 0.38, f_B = 1.08 - 1.12, and f_{hep} = 1 - 4. With respect to this best fit the LOW solution is accepted at 90% C.L.. The Vacuum oscillation solution with \Delta m^2 = 1.4 10^{-10} eV^2, gives good fit of the data provided that the boron neutrino flux is substantially smaller than the SSM flux (f_B \sim 0.5). The SMA solution is accepted only at 3\sigma level. We find that vacuum oscillations to sterile neutrino, VAC(sterile), with f_B \sim 0.5 also give rather good global fit of the data. All other sterile solutions are strongly disfavored. We check the quality of the fit by constructing the pull-off diagrams of observables. Predictions for the day-night asymmetry, spectrum distortion and NC/CC ratio at SNO are calculated. In the best fit points of the global solutions we find: A_{DN}^{CC} \approx (7 - 8)% for LMA, \sim 3% for LOW, and (2 - 3)% for SMA. It will be difficult to see the distortion of the spectrum expected for LMA as well as LOW solutions. However, future SNO spectral data can significantly affect the VAC and SMA solutions. We also calculate expectations for the BOREXINO rate.Comment: 35 pages, latex, 9 figures; results of analysis slightly changed due to different treatment of the hep neutrino flux; predictions for NC/CC ratio and Borexino rate adde